ASIT biotech announced the publication of a mechanistic (mode of action) study of gp-ASIT+™, its product candidate for grass pollen allergy, in the Journal of Allergy and Clinical Immunology (JACI), the most cited peer-reviewed journal in the field of allergy and clinical immunology. The recently published data were obtained in the framework of the first Phase III clinical study (2016-2017) in collaboration with Imperial College London. As planned before the start of the clinical study, the subset of 32 patients (21 treated and 11 placebo) recruited at the University Hospital Ghent (Belgium) gave blood samples for the study of the mechanism of action of gp-ASIT+™. The data demonstrate that a short-course treatment (3 weeks) with gp-ASIT+™ is associated with the activation of regulatory immune mechanisms that protect patients against grass pollen allergy. This immunologic effect persisted until the end of the pollen season. It is noteworthy that gp-ASIT+™ induced a reduction of the combined clinical symptom and medication score (CSMS) of -35.1% (p=0.03) during the peak season and -53.7% (p=0.03) during the entire pollen season in patients that went through immunologic analyses. These results obtained without the use of adjuvants demonstrate the potency of a treatment with ASIT+™ peptides. This data further supports that gp-ASIT+™ could become an efficient and safe treatment for patients suffering from grass pollen allergy.